Diagenode

News

PRESS RELEASE
November 8, 2013

Diagenode Launches Extensively Validated Epigenetic Antibodies for Broad Research Use

Industry’s most highly validated antibodies as used by the BLUEPRINT Epigenome Consortium researchers are now broadly available for epigenetics researchers worldwide.

Diagenode, Inc., a leading global provider of complete solutions for epigenetics research, recently launched its “Premium” line of antibodies for epigenetics applications such as chromatin immunoprecipitation (ChIP) and DNA methylation. These antibodies have been extensively validated for high sensitivity and specificity through a multi-step process including assessment through ELISA, dot blot, peptide arrays, Western blot, IF, CHIP-qPCR, and ChIP-seq. They were initially developed in a collaborative effort for the well-known BLUEPRINT Epigenome consortium and now have been released for widespread research use.

 

Read more

イベント

  • Japanese Biochemical Society
    Yokohama
    Sep 18-Sep 20, 2019
  • The 2019 PacBio Long-Read Revolution: Highly Accurate and Affordable SMRT Sequencing
    Atlanta, Georgia
    Sep 19, 2019
  • The 2019 PacBio Long-Read Revolution: Highly Accurate and Affordable SMRT Sequencing
    RTP, North Carolina
    Sep 20, 2019
  • EpiGeneSys
    London
    Sep 22-Sep 24, 2019
 すべてのイベントを見る

         Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics